Mirvetuximab
immunogen
['gyn', 'ovarian']
 amazing to see in overall survival for mirvetixumab in folr1 positive platinum resistant #ovariancancer. absolutely new standard of care!! #gyncsm #asco23 
Breast & gyn med onc @valleyhealthnj. Opinions my own. RT not endorsements. Host of INTERLUDE podcast 🎤 ASCO FCOI= https://t.co/C54erlhQe8